AstraZeneca receives more funding to develop the vaccine

By: Miguel A. Rodriguez

09:45, 14 September 2020

International organizations pledge money to secure doses.

The British drugmaker, which earlier this year joined forces with Oxford University to create, manufacture and distribute the medicine developed by the university against the novel virus, recently got another vote of confidence.

At the end of May, the manufacturer agreed with the U.S. Government to receive $1 billion to speed up the process and to provide the first batch of vaccines in October. The country is to receive 300 million doses.

But the U.S. is not the first country that has secures some batches. The U.K. government financed the company with more than 130 million pounds and obtained 30 million out of 100 million doses for September.

Now, AstraZeneca signed new agreements that allow a broader distribution of the vaccine around the globe. To manufacture the drug, the company would receive $750 million, and allocated 300 million doses for global distribution through international foundations. Moreover, one billion doses will go to low-and middle-income countries as part of the agreement with the Serum Institute of India – an essential manufacturer of low-cost vaccines. Four hundred million doses must be provided by the end of the year.

According to Pascal Soriot, CEO of AstraZeneca, the manufacturing process has already begun. 

AstraZeneca’s stock price gained more than 0.40% during today's pre-market session.

Knowledge is power, so find out more about the market! Register now!

Sources: marketwatch.com, bbc.com, reuters.com

Share this article

This information prepared by capex.com/za is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of capex.com/zaJME Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.